Blog

The following is an excerpt from a recent scientific publication:“For most proteins in the genome databases, function is predicted via sequence comparison. In spite of the popularity of this approach, the extent to which it can be reliably applied is unknown. We address this issue by systematically investigating the relationship between protein function and structure. We focus initially on enzymes functionally classified by the Enzyme Commission (EC) and relate these to structurally classified domains the SCOP database. We find that the major SCOP fold classes have different propensities to carry out certain broad categories of functions.” According to the excerpt, which structural classification is most predictive of enzyme functional categories?

Which combination best describes the functional specialization of myoglobin and hemoglobin in oxygen handling in the body?

Which type of bond is not typically involved in maintaining tertiary structure?

Which of the following amino acids is the least likely to be found in the interior of a globular protein?

A peptide bond is an example of which type of interaction?

Which situation below would most weaken a hydrogen bond between two molecules?

Which amino acid has a side chain that, due to its small size and lack of chirality, introduces conformational flexibility in protein loops?

A salt bridge in a protein structure is best described as:

Which of the following functional groups typically behaves as an electrophile in organic reactions?

The following is an excerpt from a recent scientific publication:“Covalent inhibitors can achieve exquisite potency and durable target occupancy through a combination of covalent and noncovalent interactions. Drugs that possess a covalent mechanism‑of‑action encompass recent blockbusters (Clopidogrel) as well as early cornerstones of modern medicine (aspirin and penicillin). Despite this well‑documented history and the advantages from sustained target engagement, pharmaceutical companies have traditionally shied away from covalent drug programs due to concerns about potential idiosyncratic toxicity. However, clinical successes over the past decade (e.g. Ibrutinib), along with improvements in technologies used throughout the drug discovery pipeline, have reignited broad interest in this class of therapeutics.” What key advantage of covalent inhibitors is emphasized here in drug discovery?